Huntington's disease is a genetic neurodegenerative disorder that affects both motor and cognitive function and gradually reduces the independence and quality of life of those affected. One of the ...

Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period. The Food and Drug ...

Huntington's chorea (also known as St. Vitus' dance) is a rare brain disorder that causes, among other symptoms, uncontrollable, jerky movements in individuals. Photo: Getty Images/Science Photo ...

SAN DIEGO, Sept. 30, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study of INGREZZA® (valbenazine) capsules ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA approved Ingrezza due to results from KINECT-HD, ...

Neurocrine Biosciences announced data from a phase 3 trial of Ingrezza that showed it reduced chorea severity among patients with Huntington’s disease. The trial, called KINECT-HD, examined the ...

The phase 3 KINECT-HD study included 128 adults 18 to 75 years of age who were diagnosed with chorea associated with HD. Positive topline data were announced from a phase 3 study evaluating the ...

Neurocrine Biosciences is a pharmaceutical company specializing in the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company recently submitted a proposal for the use ...

Chorea Huntington (known as "Veitstanz" in German) is a rare brain disorder that causes uncontrollable, jerky movements in individuals. Photo: Getty Images/Science Photo Library RF Huntington’s ...

SAN DIEGO, Nov. 2, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced interim results from the ongoing open-label KINECT®-HD2 study about INGREZZA® (valbenazine) capsules ...

SAN DIEGO, Aug. 28, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data on now FDA-approved INGREZZA® (valbenazine) capsules for the treatment of adults with ...